Daiichi Sankyo and Merck enter into global agreement for MK-6070
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Revolutionary technology will further boost OneSource’s scientific services offerings
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Subscribe To Our Newsletter & Stay Updated